Late-Breaking Abstract Parallel sessions feature oral presentations from the authors of cutting-edge, highly-rated abstracts submitted for presentation at The Liver Meeting.
Presentations
5:15 PM
- 5:30 PM
Apr
29
2026
Washington, D.C.
Sustained and Clinically Meaningful Improvements in Moderate to Severe Pruritus Patients With Primary Biliary Cholangitis Treated With Seladelpar: Results From the ASSURE Study up to 30 Months
Gideon M Hirschfield, FRCP, PhD
, Abstract Presenter
6:15 PM
- 6:30 PM
Apr
29
2026
Washington, D.C.
Once-monthly Efimosfermin Alfa for Up to 48 Weeks in Metabolic Dysfunction-Associated Steatohepatitis with F2/F3 Fibrosis: Results from a Phase 2, Open-Label Extension Study
Mazen Noureddin
, Abstract Presenter
Objectives
Review findings from recent clinical trials related to treatments for hepatitis, MASH, and PBC.